Asbestosis

Background

  • Asbestosis is an irreversible, progressive interstitial pulmonary fibrosis caused by inhalation of asbestos fibers, characterized by basal-predominant fibrosis and typically accompanied by pleural plaques.[1] It clinically resembles idiopathic pulmonary fibrosis (IPF) but progresses more slowly.
  • Asbestosis is one of several asbestos-related diseases, which also include benign pleural effusion, pleural plaques, diffuse pleural thickening, rounded atelectasis, lung cancer, and mesothelioma.[2] The latency period from first exposure to disease is typically >20 years.[2] The most common malignancy associated with asbestos exposure is lung cancer, not mesothelioma.[2] There is no cure — management is supportive.
  • The ED physician's key roles are recognizing asbestos-related disease on imaging, evaluating acute complications, screening for malignancy, and ensuring appropriate occupational medicine referral.
  • Asbestos is a group of naturally occurring silicate mineral fibers historically used in insulation, fireproofing, roofing, brake linings, cement, shipbuilding, textiles, and gaskets[1]
  • Two fiber types:
    • Amphibole (amosite, crocidolite, tremolite) — straight, rigid needles; more fibrogenic and carcinogenic; most strongly linked to mesothelioma[3]
    • Serpentine (chrysotile) — curly fibers; accounts for >90% of asbestos used commercially worldwide; less fibrogenic but still carcinogenic[1]
  • High-risk occupations: Shipyard workers, construction workers (especially demolition/renovation of older buildings), insulation installers/removers, plumbers, pipefitters, electricians, boilermakers, brake mechanics, roofers, naval personnel, miners, power plant workers[1]
  • Passive/household exposure: Workers carrying asbestos fibers home on clothing → household contacts (especially mesothelioma risk); residential proximity to asbestos mines or processing plants[1]
  • Latency: Typically 20–40 years from first exposure to clinical disease; asbestos-related diseases may continue to present decades after exposure ceased[1]
  • Pathogenesis: Inhaled asbestos fibers reach alveoli → phagocytosed by macrophages → fibers cannot be cleared → chronic inflammation → fibroblast activation → dose-dependent interstitial fibrosis (peribronchiolar and subpleural)[1]
  • Asbestos bodies: Iron-coated asbestos fibers visible on light microscopy as golden-brown, dumbbell-shaped structures; marker of asbestos exposure but not disease[1]
  • Smoking interaction: Smoking does not increase mesothelioma risk, but has a multiplicative effect on lung cancer risk in asbestos-exposed individuals (~50-fold combined risk vs. ~5-fold for asbestos alone and ~10-fold for smoking alone)[1]
  • Spectrum of asbestos-related disease:
    • Benign: Pleural plaques (most common manifestation of asbestos exposure), diffuse pleural thickening, benign asbestos-related pleural effusion (BAPE), rounded atelectasis, asbestosis
    • Malignant: Lung cancer (most common malignancy), malignant mesothelioma (pleural > peritoneal > pericardial), laryngeal cancer, ovarian cancer[2]
  • US EPA moved toward a comprehensive ban on asbestos in 2024; asbestos is already banned in >60 countries worldwide[2]

Clinical Features

  • Insidious onset — symptoms typically appear 20–30+ years after initial exposure[1]
  • Progressive exertional dyspnea — the most common and often earliest symptom
  • Persistent dry cough (may become productive with superimposed infection)
  • Fatigue, reduced exercise tolerance
  • Chest tightness or vague chest discomfort
  • Physical exam:
    • Bibasal end-inspiratory ("Velcro") crackles — the hallmark finding; identical to those in IPF[1]
    • Digital clubbing — present in advanced disease (~40–50% of cases); more common than in most other pneumoconioses[1]
    • Cyanosis in advanced disease
    • Signs of right heart failure/cor pulmonale in end-stage disease (elevated JVP, peripheral edema, hepatomegaly)
  • Pleural plaques are usually asymptomatic and are a marker of exposure, not disease severity — however, their presence strongly supports asbestos as the etiology of any concurrent fibrosis[1]
  • Asbestos-related pleural effusion (BAPE):
    • Usually occurs earlier than asbestosis (within 10–20 years of exposure)
    • Typically small, unilateral, exudative, often hemorrhagic
    • Diagnosis of exclusion — must rule out mesothelioma (requires thoracoscopy/biopsy in many cases)[1]
    • May be recurrent; may resolve spontaneously
  • Rounded atelectasis: Subpleural mass-like opacity with "comet tail" of bronchovascular structures; can mimic lung cancer on imaging; results from folding of thickened visceral pleura[1]

ED presentations:

  • Progressive dyspnea in a patient with known or newly discovered asbestosis
  • Acute respiratory infection superimposed on chronic fibrosis
  • New pleural effusion requiring evaluation (BAPE vs. mesothelioma vs. infection vs. CHF)
  • Incidental pleural plaques found on CXR or CT — triggers need for occupational history and referral
  • Hemoptysis (raises concern for lung cancer or mesothelioma)
  • Acute chest pain + effusion + weight loss → mesothelioma until proven otherwise
  • Respiratory failure in end-stage disease

Differential Diagnosis

  • Idiopathic pulmonary fibrosis (IPF) — the most important differential; both cause basal-predominant fibrosis with UIP pattern; differentiated by exposure history and presence of pleural plaques; asbestosis progresses more slowly than IPF[2]
  • Other pneumoconioses: Silicosis (upper-lobe predominant; round opacities; different exposure), chronic beryllium disease (granulomatous; BeLPT positive)
  • Connective tissue disease-associated ILD (rheumatoid arthritis, scleroderma)
  • Hypersensitivity pneumonitis (fibrotic HP — exposure history differs; often upper/mid zone; air trapping; rare pleural involvement)
  • Drug-induced pulmonary fibrosis (amiodarone, methotrexate, bleomycin, nitrofurantoin)
  • Sarcoidosis (upper-zone predominant; hilar lymphadenopathy; non-caseating granulomas)
  • Radiation fibrosis
  • For pleural disease:
    • Mesothelioma (nodular pleural thickening; circumferential; effusion; weight loss)
    • Metastatic pleural disease
    • Tuberculosis (pleural effusion, especially in endemic areas)
    • CHF (bilateral effusions; cardiomegaly)


Pulmonary Fibrosis

Evaluation

Workup

History — essential:

  • Detailed lifetime occupational history: All jobs held; specifically ask about shipyards, construction, demolition, renovation of pre-1980s buildings, insulation work, plumbing, brake repair, roofing, mining, power plants, naval service
  • Household/environmental exposure: Lived with asbestos worker; proximity to asbestos processing; older home with deteriorating insulation
  • Latency from first exposure (usually >20 years)
  • Smoking history (critical for lung cancer risk stratification — multiplicative interaction)
  • Prior asbestos-related disease (pleural plaques, prior effusions)
  • Symptoms suggesting malignancy: weight loss, night sweats, new chest wall pain, hemoptysis, rapidly increasing effusion

Laboratory (ED):

  • CBC, CMP
  • ABG/VBG: Hypoxemia (exercise-induced desaturation is early finding)
  • BNP/NT-proBNP if right heart failure suspected
  • If pleural effusion tapped: cell count, LDH, protein, glucose, pH, cytology, triglycerides (rule out chylothorax from lymphatic obstruction by mesothelioma)
  • No specific serum biomarker for asbestosis
  • Mesothelin (SMRP): A serum biomarker under investigation for mesothelioma screening — not yet standard of care and not an ED test[3]

Imaging:

Chest X-ray:

  • Normal in 10–20% of patients with histologically confirmed asbestosis[1]
  • Bilateral, basal-predominant reticulonodular opacities — the classic finding
  • Pleural plaques: Discrete areas of pleural thickening, often calcified, typically bilateral, along posterolateral chest wall (ribs 7–10), diaphragm, and mediastinal pleura; apices and costophrenic angles are typically spared[4]
  • "Shaggy" cardiac silhouette and diaphragmatic contours — from basal fibrosis obscuring smooth borders[5]
  • Diffuse pleural thickening (continuous sheet, may obliterate costophrenic angles — unlike focal plaques)
  • Rounded atelectasis: Subpleural rounded opacity with "comet tail" sign
  • Pleural effusion (unilateral or bilateral)
  • CXR sensitivity for pleural plaques: only 50–80% compared to CT[1]

HRCT — the key imaging modality:

  • Subpleural "dotlike" opacities and subpleural curvilinear lines — earliest HRCT findings of asbestosis; represent peribronchiolar fibrosis[4]
  • Intralobular and interlobular septal thickening (basal-predominant)
  • Parenchymal bands (linear opacities 2–5 cm extending from pleura into lung)
  • Honeycombing in advanced disease (identical to UIP/IPF pattern)
  • Pleural plaques — HRCT is far more sensitive than CXR; presence alongside basal fibrosis is virtually diagnostic of asbestosis in the appropriate clinical context[1]
  • Prone images are essential — distinguish true subpleural fibrosis from dependent atelectasis (gravity-related opacity in supine position)[4]
  • Key distinction from IPF: Subpleural dotlike opacities, parenchymal bands, and mosaic perfusion are more common in asbestosis; visible intralobular bronchioles and honeycombing are more prominent in IPF[6]
  • Rounded atelectasis: Round/oval mass abutting thickened pleura with "comet tail" of curving bronchovascular bundles entering the mass — do NOT mistake for lung cancer (CT appearance is usually diagnostic; PET may be falsely positive)[1]

PFTs (outpatient):

  • Restrictive pattern: Reduced FVC, reduced TLC[1]
  • Reduced DLCO — often the earliest functional abnormality; correlates with extent of fibrosis
  • Exercise-induced desaturation (useful for detecting early disease)
  • Obstructive component may be present (airway involvement, concurrent COPD from smoking)

Diagnosis

  • Clinical-radiographic diagnosis based on:[1]
    • (1) Reliable history of asbestos exposure with appropriate latency (typically >20 years)
    • (2) Imaging consistent with asbestosis (basal-predominant fibrosis on CXR or HRCT)
    • (3) Exclusion of other causes of pulmonary fibrosis
  • Presence of pleural plaques alongside basal fibrosis greatly increases diagnostic confidence — plaques are a reliable marker of asbestos exposure[1]
  • Lung biopsy is rarely required — clinical-radiographic diagnosis is sufficient in most cases; biopsy only when diagnosis is uncertain and management would change[1]
  • If biopsied: Peribronchiolar and subpleural fibrosis with asbestos bodies (golden-brown, dumbbell-shaped, iron-coated fibers) on light microscopy[1]
  • In the ED: Consider asbestosis when you see bilateral basal fibrosis + pleural plaques on imaging — obtain occupational history and ensure pulmonology/occupational medicine referral

Management

There is no cure for asbestosis and no specific treatment — management is entirely supportive[7]

1. Remove from further asbestos exposure — though disease typically diagnosed long after exposure has ceased

2. ED management of acute presentations:

  • Supplemental O2 to maintain SpO2 ≥90%
  • Bronchodilators for patients with reversible airway component
  • Treat superimposed respiratory infections with appropriate antibiotics
  • Non-invasive ventilation or intubation for respiratory failure
  • Treat right heart failure/cor pulmonale (diuretics, O2)
  • Thoracentesis for symptomatic pleural effusion — always send cytology to evaluate for mesothelioma; hemorrhagic exudative effusion in an asbestos-exposed patient requires thoracoscopy/biopsy if cytology is negative[1]

3. Malignancy surveillance — critical responsibility:

  • Lung cancer: The most common asbestos-related malignancy; risk is multiplicative with smoking (~50× for combined exposure); consider low-dose CT screening per USPSTF guidelines in appropriate patients; smoking cessation is the single most impactful intervention for reducing lung cancer risk in asbestos-exposed individuals
  • Mesothelioma: Latency 25–70 years (median 30–40 years) after first exposure; insidious onset with dyspnea, chest wall pain, and pleural effusion (present in ~90%); median survival 12–21 months; treatment: nivolumab + ipilimumab (FDA-approved for unresectable mesothelioma), surgery (pleurectomy/decortication or extrapleural pneumonectomy in selected patients), chemotherapy (cisplatin + pemetrexed), radiation[3]
  • Any new pleural effusion, pleural thickening, or chest wall pain in a patient with asbestos exposure history warrants aggressive evaluation for mesothelioma

4. Long-term management (coordinate with pulmonology/occupational medicine):

  • Smoking cessation (mandatory — reduces lung cancer risk)
  • Pulmonary rehabilitation
  • Supplemental O2 for chronic hypoxemia
  • Annual influenza vaccination; pneumococcal vaccination; COVID-19 vaccination
  • Serial PFTs to monitor progression
  • Low-dose CT lung cancer screening (per USPSTF criteria)
  • Lung transplantation for end-stage fibrosis (rare; most patients are elderly with comorbidities)
  • No proven antifibrotic therapy for asbestosis specifically (nintedanib/pirfenidone have not been specifically studied)

5. Reporting and compensation:

  • Document exposure history thoroughly — asbestosis is a compensable occupational disease
  • Report to occupational health/public health authorities as required
  • Patients may be eligible for workers' compensation, asbestos trust fund compensation, or legal claims
  • Workplace contacts may need evaluation (household contacts at risk for mesothelioma from passive exposure)

Disposition

  • Admit:
    • Respiratory failure or significant new hypoxemia
    • New pleural effusion requiring evaluation (especially if concern for mesothelioma — expedite thoracoscopy/biopsy)
    • Hemoptysis requiring evaluation (lung cancer vs. infection)
    • Severe respiratory infection superimposed on chronic fibrosis
    • Cor pulmonale/right heart failure
  • Discharge with close follow-up:
    • Stable known asbestosis with symptoms at baseline
    • Incidental finding of pleural plaques in an asymptomatic patient — arrange occupational medicine/pulmonology referral for baseline PFTs and HRCT
    • New suspected asbestosis in stable patient — arrange:
      • Pulmonology and/or occupational medicine referral within 1–2 weeks
      • HRCT with prone images if not performed
      • PFTs with DLCO
      • Low-dose CT lung cancer screening discussion
  • Discharge counseling:
    • Return for worsening dyspnea, hemoptysis, new chest pain, or fever
    • Smoking cessation (most important modifiable risk factor for lung cancer)
    • Avoid further asbestos exposure (especially during home renovation of older buildings)
    • All household contacts of asbestos workers should be informed of mesothelioma risk
    • Report exposure to occupational health for workplace evaluation

See Also

External Links

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Asbestos-related diseases. AMBOSS. Updated 2024.
  3. ↑ 3.0 3.1 3.2 Malignant Mesothelioma. StatPearls. NCBI Bookshelf. Updated January 2025.
  4. ↑ 4.0 4.1 4.2 Asbestosis Imaging. Medscape/eMedicine. Updated 2024.
  5. ↑ Asbestos: when the dust settles — an imaging review of asbestos-related disease. RadioGraphics. 2002;22(suppl):S167-S184.
  6. ↑ Akira M, et al. High-resolution CT of asbestosis and idiopathic pulmonary fibrosis. AJR Am J Roentgenol. 2003;181(1):163-169.
  7. ↑ Asbestosis. Merck Manual Professional Edition. Updated April 2025.
This page is issued from WikEM. The text is available under an unknown license unless otherwise noted. Additional terms may apply for the media files.